Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Mount Sinai Cancer Center, Miami Beach, FL, United States

Survival: 14.9 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Miami Beach, FL
Hospital: Mount Sinai Cancer Center
Journal: Link
Date: 2/2008

Patients: This phase II trial involved 103 patients with advanced non-small-cell lung cancer.

Treatment: Patients were treated with either erlotinib (a biological therapy) or paclitaxel and carboplatin (chemotherapy drugs).

Toxicity: Three patients died from causes related to treatment, one receiving erlotinib and two receiving chemotherapy. One patient died from pulmonary infiltrates and interstitial lung disease, and the other two died from febrile neutropenia. Grade 4 pulmonary embolism was reported, as were grade 3 diarrhea, anemia, thrombocytopenia, and elevated liver enzymes.

Results: The median overall survival was 6.6 months for patients treated with erlotinib and 9.5 months for those treated with the chemotherapy drugs (paclitaxel and carboplatin). Some patients treated with chemotherapy switched to erlotinib, and the median overall survival of these twenty-nine patients was 14.9 months.

Support: This study was supported by OSI Pharmaceuticals, Inc. This company markets erlotinib as TarcevaŽ (through a partnership with Genentech, the U.S. and with Roche in other countries).

Correspondence: Dr. Rogerio Lilenbaum

E-mail to a Friend Email Physician More Information